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Abstract

SARS-CoV-2 is a novel beta coronavirus that emerged in 2019 and is responsible for the on-going pandemic
(COVID-19). The humoral immune response consists of antibodies of multiple isotypes that can block viral
progression. We wanted to characterize antibody response to a vaccine (Pfizer, BNT162b2) in a group of Children’s
Mercy employees. We compared responses of people with previous SARS-CoV-2 infection (COVID19+) to those
with no known previous infection (COVID19-). We measured antibody isotypes IgG, IgM and IgA to SARS-CoV-2
spike protein subunit 1 (S1), spike protein subunit 2 (S2), receptor binding domain (RBD), and nucleocapsid (NP) at
baseline (week 0), after the first dose (week 3) and after the second dose (week 7). At baseline, the COVID19+
group had levels of IgG to S1, S2, RBD, NP that were significantly higher than the COVID19- group. After the first
dose, the COVID19+ group continued to show significantly higher IgG levels to S1, S2, RBD, NP. The COVID19- group
had variable IgG levels, suggesting that protection after the first vaccine is not guaranteed. Due to the extremely
high levels of IgG in COVID19+ group after the first dose, these individuals may only require one vaccination. At the
final time point, COVID19- had similar IgG levels to S1, S2, and RBD as the COVID19+ group; indicating that
protection from the second vaccination was complete. Neutralizing antibody levels were also determined
throughout the course of immunization. The COVID19+ group had significantly higher neutralizing antibodies
compared to the COVID19- group at baseline and after the first dose. After the second dose, nearly all participants
had high (<85%) neutralizing antibodies present. Finally, using the spike protein we identified regions of high IgG
reactivity that may be excellent targets for future vaccine design.
Antibodies can target conserved sites on the virus and cross-react with multiple related coronaviruses. Children are
often more recently infected with seasonal coronaviruses than adults and are more resistant to severe COVID-19
disease. It was previously reported that children have high levels of cross-reactive antibodies to SARS-CoV-2
despite never having infection. We wanted to confirm if children have higher levels of cross-reactive antibodies
than adults, and further characterize these responses. We measured antibody isotypes in children never exposed
to SARS-CoV-2 (cohort from 2017/2016). We found that a portion of children had pre-existing cross-reactive
antibodies, and that these antibodies were also present in some adults with no prior history of SARS-CoV-2
infection.

Antibody subclass responses after SARS-CoV-2 Antibody subclass responses after SARS-CoV-2
infection and in healthy populations
immunization in seronegative individuals
(A) Multiplex bead-based antibody binding assays that
measures relative antibody levels to SARS-CoV-2
nucleocapsid protein (NP) and spike subunit proteins
S1, S2 and Receptor Binding Domain (RBD) by
antibody isotype IgG, IgM or IgA in seronegative
individuals at baseline (day 0; n=146; blue),
seronegative three weeks after primary BNT162b2
COVID-19 vaccine (Week3; n=140; red) and
seronegative four weeks after secondary COVID-19
vaccine (Week7; n=131; green). Seropositive
individuals shown for comparison (Figure 1; n=44;
purple). Median Fluorescent Intensity (MFI) is shown
and has been background subtracted. Each point
represents an individual and solid lines represent
population medians. Dashed line indicates a threshold
determined by the sum of the average and standard
deviation of the negative control (beads without
antigen). (B-C) Neutralization antibody proxy assay
that determines the level of antibodies that block
binding of the spike protein receptor-binding domain
(RBD) to the human host receptor angiotensinconverting enzyme 2 (ACE2) expressed as the
percentage of binding that was blocked relative to a
control with no plasma. Each point represents an
individual and lines represent group median. (B) 26
seronegative individuals at baseline, three weeks after
primary BNT162b2 COVID-19 vaccine (week3; n=140;
red) and four weeks after secondary COVID-19 vaccine
(week7; n=131; green). SARS-CoV-2 infected
seropositive individuals shown for comparison (Figure
1; n=44; purple). (C) The infected seropositive
individuals (n=44) stratified by the days after initial
SARS-CoV-2 infection. Statistical differences between
groups were determined by Wilcoxon-Mann-Whitney
tests.

Background and Introduction

The humoral response consists of multiple antibody types with
differential structures and functions.
• Immunoglobulin M (IgM) which is a pentamer
• Immunoglobulin A (IgA) more prevalent in the respiratory and
gastrointestinal tract
• Immunoglobulin G (IgG) main type found in blood and
extracellular fluid
• Immunoglobulin O (IgO) & Immunoglobulin E (IgE)

SARS-CoV-2 structure includes:
• Spike protein 1 (S1)
• Spike protein 2 (S2)
• Nucleocapsid (NP)
• Membrane (M)
• Receptor binding domain (RBD)
• Single stranded RNA (ssRNA)

High-resolution mapping of SARS-CoV-2
antibody responses

High-resolution mapping of SARS-CoV-2
antibody responses after COVID-19 vaccine
(A-B) Plasma IgG binding to SARS-CoV-2 peptides spanning the SARS-CoV-2 spike protein ((A) S1 and (B) S2 subunits separated;12-mer overlapping peptides).
Each peptide printed in triplicate and the Log2 of the mean fluorescent intensity (F635) for each peptide graphed. Row color corresponds to minimum and
maximum intensity for all peptides for each individual. Seropositive (top) represent 14 individuals previously infected with SARS-CoV-2 (I1-I14) and
seronegative (bottom) represent seven children (C1-C7) and seven adults (A1-A7) collected prior to COVID-19 pandemic. Known regions of the spike protein
are annotated above heatmaps. (C) Heatmap of calculated Z-scores for peptides that have significant (Adj. P ≤ 0.05, t-test) differences in binding intensities
between seropositive and seronegative individuals. (D) Bar graphs displaying the peptides that are recognized by the largest number of individuals (positivity
determined by a Z-score ≥ 0) in the seropositive group (n=14, top) and seronegative group (n=14, bottom). Frequencies of positivity for the seropositive
(blue) and seronegative (red) graphed for each peptide on both graphs.

When the body is exposed to SARS-CoV-2 the antibody response is launched is defined by and increase in IgM and IgG to multiple
parts of the virus. IgM/G have been reported to persist at least for 6 months post-infection (Wu J. et al. Nature 2021). Cross- reactive
antibodies (IgG) generated to S2 from seasonal coronavirus to infection to SARS-CoV-2 have been identified in children and may
explain decrease of disease severity in that group (Ng K et al. Science 2020).

Conclusions & future directions

Goal & Approach

Our first goal was to characterize the antibody response to the vaccine.
Our second goal was to characterize cross-reactive antibodies in children and determine if they
offer protective immunity.
To do this we:
1) measured types and levels of antibodies present (IgG/M/A) to different parts of the
SARS-CoV-2 virus (S1,S2, RBD, NP)
2) measured neutralizing antibody levels
3) conducted high-resolution antibody epitope mapping

(A-C) Multiplex bead-based antibody binding assays that measures relative antibody levels to SARS-CoV-2 nucleocapsid protein (NP) and spike subunit
proteins S1, S2 and Receptor Binding Domain (RBD) by antibody isotype IgG, IgM or IgA in (A) 44 SARS-CoV-2 infected individuals (n=44) (B) SARS-CoV-2
negative healthy adults (n=44) and (C) SARS-CoV-2 negative children of ages 0-15 years old (n=86). Median Fluorescent Intensity (MFI) is shown and has been
background subtracted. Each point represents an individual and solid lines represent population medians. Dashed line indicates a threshold determined by
the sum of the average and standard deviation of the negative control (beads without antigen). The numbers above each antigen are the numbers of
individuals above the determined threshold. (D) Bar graphs for each antibody isotype that shows the percent of SARS-CoV-2 negative individuals in each age
group (blue, adult; red, 0-1 years old; green, 2-10 years old; purple, 11-15 years old) that were positive for antibody using a conservative threshold of the
average plus standard deviation of the whole group (adults + children) MFI values.

(A-D) Plasma IgG binding to SARS-CoV-2 peptides spanning the SARS-CoV-2 spike protein ((A) S1 and (C) S2 subunits separated;12-mer overlapping
peptides) in 14 SARS-CoV-2 seronegative adults after primary COVID-19 immunization (week 3). Each peptide printed in triplicate and the Log2 of the
mean fluorescent intensity (F635) for each peptide graphed. Row color corresponds to minimum and maximum intensity for all peptides for each
individual. Known regions of the spike protein are annotated above heatmaps. (B & D) Line graphs displaying the mean group Z-score for each peptide in
(B) S1 and (D) S2 from the vaccine group (blue; n=14), seronegative group (green; n=14) or seropositive group (red; n=14). (E) Heatmap of calculated Zscores for peptides that have significant (Adj. P ≤ 0.05, t-test) differences in binding intensities between the vaccine group and seropositive individuals.
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For Seronegative (COVID19-)- Antibody response to the vaccine for S1, S2 & RBD increased significantly from baseline to week 3 (IgG>IgM>IgA) and
continued to increase at week 7 after second dose. Antibody response did not increase significantly to NP. Neutralizing antibodies were highly variable at
week 3 after the first dose, but at week 7 after the second dose almost all samples contained >80% neutralizing abilities.
For Seropositive (COVID19+)- Antibody response to the vaccine resulted in even higher levels of IgG/M/A to S1, S2, RBD at week 3. These levels are like
those of COVID19- at week 7. Antibody response to NP remained high throughout the vaccination and acts as a marker of natural infection. Neutralizing
antibody levels at baseline were higher than COVID19- and sharply increased with vaccination at week 3 and remained high at week 7.
Epitope mapping- SARS-CoV-2 mRNA vaccine immunodominant regions are targeted similarly to natural infection.
Pre-existing immunity - In both adults and children, preexisting antibody immunity to the S1 antigen was rarely detectable, but antibodies recognizing the NP,
S2 and RBD were detected more frequently for IgG and IgM isotypes. Antibodies of the IgA isotype were only rarely above the threshold.
Future directions: We will continue to monitor long-term immunity in this group to determine how long protective antibodies last. Highly active regions have
been identified as future vaccine design targets, further testing of these immunizing peptides will be done
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